Crossmark

A Population Pharmacokinetic and Pharmacodynamic Analysis of RP5063 Phase 2 Study Data in Patients with Schizophrenia or Schizoaffective Disorder

Published Online: 2018-04-04

Published Print: 2018-10

Authors

Cantillon, Marc

Ings, Robert

Prakash, Arul

Bhat, Laxminarayan http://orcid.org/0000-0003-0503-8537
Funding

Funding for this research was provided by:

Reviva Pharmaceuticals, Inc (Not applicable)
License Information

Text and Data Mining valid from 2018-04-04
More Information

Article History

First Online: 4 April 2018

Compliance with Ethical Standards

:

: Reviva Pharmaceuticals, Inc. provided sponsorship funding for the REFRESH clinical trial and for a grant to Davide Verotta, PhD for population analysis, and for editorial development by Akita Biomedical, Inc.

: Arul Prakash, M. Pharm., Laxminarayan Bhat, PhD, and Marc Cantillon, MD are employees of Reviva Pharmaceuticals, Inc., and Robert Ings, PhD is a consultant to Reviva Pharmaceuticals, Inc.

: All procedures performed in the phase 2 REFRESH trial were in accordance with the 1964 Helsinki declaration (and its amendments). This study was approved by institutional review boards for each of the investigative sites located in India, Philippines, Malaysia, Moldova, and USA. Written informed consent was obtained from participants directly, or from parents or care givers of all participants.

Document is current